outcomes matter -- oncotype dx®
Published 2 years ago • 2.1K plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
1:53
oncotype dx - outcomes matter
-
9:00
exact sciences - oncotype dx ® test can help certain types of breast cancer avoid chemotherapy
-
33:23
oncotype dx breast recurrence score assay after tailorx and rxponder: what’s next?
-
9:45
exact sciences - genomic prostate score ® (gps™) test and adverse pathology
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
25:56
dcis diagnosis & the oncotype breast cancer assay for dcis
-
12:19
active surveillance 2022: who qualifies, who does not and how should it be monitored
-
9:11
publication of 20-year outcomes of oncotype dx gps test
-
9:31
sabcs - data on exact sciences' oncotype dx in guiding treatment decisions
-
8:23
steve shak, asco 2020: the oncotype dx breast recurrence score® test
-
9:13
exact sciences - oncotype map™ pan-cancer tissue test
-
1:34
how do you communicate the oncotype dx test results?
-
2:34
oncomap™ physician overview video
-
1:27
the value of an intermediate recurrence score® result in the oncotype dx® breast cancer assay
-
5:47
the impact of the oncotype dx® recurrence score® on treatment decisions in breast cancer patients
-
58:15
science says: the promise of precision oncology
-
0:59
dr. tripathy on the oncotype dx assay recurrence score
-
1:14:42
her speaker series: understanding genetic testing vs. tumor-based testing
-
3:40
oncotype dx test importance
-
8:07
point-counterpoint q&a w/ dr. klein: oncotype dx genomic prostate score in active surveillance
-
26:30
webinar oncotype dx® breast recurrence score